Related Experiment Videos
Thrombolysis for acute stroke: is it for everyone?
S Sundararajan1, L B Morgenstern
1Department of Neurology at University Hospitals of Cleveland and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Sundarar@aol.com
Current Atherosclerosis Reports
|December 21, 2000
Summary
The only FDA-approved stroke treatment, recombinant tissue plasminogen activator (rt-PA), benefits many patients within 3 hours. Careful patient selection is crucial to balance benefits against the risk of hemorrhagic conversion in acute ischemic stroke.
Area of Science:
- Neurology
- Emergency Medicine
- Pharmacology
Background:
- Limited treatment options exist for acute stroke.
- Recombinant tissue plasminogen activator (rt-PA) is the sole FDA-approved therapy.
- Early treatment improves outcomes but carries risks.
Purpose of the Study:
- Review evidence for intravenous and intra-arterial thrombolytics.
- Define optimal patient selection criteria for rt-PA.
- Outline a framework for rt-PA administration and discuss future directions.
Main Methods:
- Literature review of thrombolytic therapy in acute stroke.
- Analysis of patient selection for rt-PA.
- Discussion of administration protocols and future therapeutic strategies.
Main Results:
- rt-PA demonstrates significant benefit for acute ischemic stroke patients within 3 hours.
- High-risk patients for hemorrhagic conversion often have the worst ischemic outcomes.
- Intravenous and intra-arterial thrombolysis are supported by data.
Conclusions:
- Thrombolytic therapy, particularly rt-PA, is a critical treatment for acute stroke.
- Careful patient selection is paramount to maximize benefits and minimize risks.
- Future research should focus on refining thrombolytic protocols and expanding therapeutic options.